|
  
- 现金
- 416 元
- 精华
- 0
- 帖子
- 277
- 注册时间
- 2017-1-7
- 最后登录
- 2024-9-28
|
A recent study, published in Internal Medicine, examined an unexpected potential side effect of the COVID-19 vaccine: HBsAg reduction in patients with chronic hepatitis B.
The investigators studied 3 clinical cases in Japan, in which chronic hepatitis B patients had a rapid decrease in their HBsAg levels after receiving a COVID-19 vaccine. All analyses with patient data were approved by the institutional research ethics committees of the International University of Health and Welfare.
To determine whether there really was a correlation between COVID-19 vaccination and HBsAg reduction, the investigators compared the number of chronic HBV patients who had a change in HBsAg levels before Japan’s COVID-19 vaccine rollout to the number of HBV patients who showed a change in HBsAg levels after COVID-19 vaccination.
A total of 107 patients were included in the analysis comparing HBsAg changes in the pre-vaccination period with the post-vaccination HBV patients. Among these, 11 patients had an HBsAg reduction of >50% per year during the post-vaccination period, 50 had a 10%-50% reduction, and 46 had a <10% decrease or an increase in HBsAg levels.
The proportion of patients whose HBsAg levels reduced by more than 50% per year was notable after the rollout of COVID-19 vaccines. At P = 0.0532, the role of COVID-19 vaccination in HBsAg reduction was not statistically significant. However, the study authors concluded, it suggests “the administration of COVID-19 vaccines may have been involved in HBsAg reduction in patients with chronic hepatitis B,” and certainly merits further investigation. |
|
发表于 2024-9-27 09:07